We scan new podcasts and send you the top 5 insights daily.
Bostwick contrasts RNAi with serendipity-discovered small molecules: programmable drugs let teams write code for a biological pathway. Because Watson-Crick base pairing in drug design gives million-to-one or better target discrimination, he argues these modalities can act upstream with specificity that was unheard of in medicine until recently.
A new class of drug called siRNA, a cousin of mRNA, can enter cells and stop a specific gene from producing a harmful protein. This enables highly targeted treatments, such as new drugs that reduce a type of cholesterol by over 95% with a single, long-lasting injection.
A convergence of DNA sequencing, CRISPR, and AI allows scientists to move beyond just understanding biology to actively intervening. Medicine is now programming cellular behavior by rewriting DNA, representing a "step function" leap in what's achievable for treating disease at its root cause.
The next breakthrough in RNA therapeutics won't come from a single innovation. It requires combining two key elements: a 'programmable' mRNA payload designed to be active only in specific cells, and a targeted delivery system to get it there. This two-part solution represents the next generation of in-vivo therapies.
In multiple instances where siRNA and ASO (antisense) therapies have been developed for the same indication, the siRNA drug has emerged with a superior overall profile across efficacy, safety, and dosing convenience. This pattern suggests siRNA is solidifying its position as the more advantageous modality.
AI isn't just for designing RNA sequences. Its real value is in creating predictive models of complex cellular functions. This allows scientists to determine the precise set of instructions (RNAs) needed to make a cell perform a complex series of tasks, like targeting a brain tumor.
Because DNA encoded libraries are built combinatorially from building blocks, millions of molecules differ by only one or two changes. This structured variation enables machine learning models to isolate exactly which chemical fragments drive target binding while keeping the rest of the molecule constant.
Human genetics doesn't just provide a drug target; it often specifies the therapeutic approach required. Discovering a protective loss-of-function mutation immediately tells researchers to develop an inhibitor (like an antibody or siRNA), accelerating the path from target discovery to molecule design.
Instead of targeting the final protein, Remix develops small molecules that intervene during pre-mRNA processing. This novel approach allows them to inhibit historically difficult drug targets like MYB, a transcription factor with no obvious binding sites, by preventing the disease-driving protein from ever being made.
The next leap in medicine isn't just delivering a payload but programming it with conditional logic. Radar Therapeutics engineers mRNA to act like software with "if/and/or" commands. This allows the therapy to sense its cellular environment and activate only in the right context, moving beyond a simple "execute" function.
Nuago leverages the 'seed-mediated off-target effect'—a bug for single-gene therapies—as a feature. Their short RNAs use a six-nucleotide seed to promiscuously target hundreds of survival and oncogenes, achieving a broad therapeutic effect where 'off-target' is the entire point, making unintended effects impossible.